Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy

European Journal of Neurology

Volumn 21, Issue 12, 2014, Pages 1465-1470

  Markvardsen, L H ^a   Harbo, T ^a   Sindrup, S H ^b   Christiansen, I ^c   Andersen, H ^a   Jakobsen, J ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Subcutaneous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN; PLACEBO; IMMUNOLOGIC FACTOR;

ADULT; AGED; APTITUDE; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; DISABILITY; DRUG INFUSION; DRUG RESPONSE; DYNAMOMETRY; FEMALE; FOLLOW UP; FUNCTION TEST; GRIP STRENGTH; HUMAN; ISOKINETIC EXERCISE; MALE; MOTOR PERFORMANCE; MUSCLE; MUSCLE FUNCTION; MUSCLE STRENGTH; PRIORITY JOURNAL; SCORING SYSTEM; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MUSCLE STRENGTH; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME;

EID: 84916211655     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12513     Document Type: Article

References (21)

1. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17: 356-363.
2. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J Peripher Nerv Syst 2010; 15: 295-301.
3. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate - chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144.
4. Markvardsen LH, Christiansen I, Harbo T, Jakobsen J. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Eur J Neurol 2014; 21: 147-152.
5. Kuitwaard K, van den Berg LH, Vermeulen M, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010; 81: 1374-1379.
6. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009; 16: 631-638.
7. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013; 20: 836-842.
8. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010; 75: 1377-1380.
9. Harbo T, Brincks J, Andersen H. Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur J Appl Physiol 2012; 112: 267-275.
10. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA; Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2003; 74: 99-104.
11. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 1985; 66: 69-74.
12. Harbo T, Andersen H, Overgaard K, Jakobsen J. Muscle performance relates to physical function and quality of life in long-term chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2008; 13: 208-217.
13. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(Pt 5): 871-882.
14. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008; 37: 406-409.
15. Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006; 253: 1505-1506.
16. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139: 133-141.
17. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15: 893-908.
18. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78: 1009-1015.
19. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345: 365-369.
20. Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005; 6: 24-29.
21. Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci 2014; 35: 1023-1034.